Head-To-Head Review: Microbot Medical (NASDAQ:MBOT) versus Vaso (OTCMKTS:VASO)

Microbot Medical (NASDAQ:MBOT) and Vaso (OTCMKTS:VASO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Valuation and Earnings

This table compares Microbot Medical and Vaso”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$11.44 million	($0.45)	-4.82
Vaso	$86.77 million	0.36	$950,000.00	$0.01	18.00

Vaso has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Vaso, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

16.3% of Microbot Medical shares are held by institutional investors. 4.7% of Microbot Medical shares are held by insiders. Comparatively, 43.9% of Vaso shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Microbot Medical has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Vaso has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Microbot Medical and Vaso, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1	1	4	0	2.50
Vaso	0	0	0	0	0.00

Microbot Medical currently has a consensus target price of $7.50, indicating a potential upside of 245.62%. Given Microbot Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Microbot Medical is more favorable than Vaso.

Profitability

This table compares Microbot Medical and Vaso’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-37.06%	-34.44%
Vaso	2.91%	9.49%	3.16%

Summary

Vaso beats Microbot Medical on 8 of the 13 factors compared between the two stocks.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

About Vaso

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.